LICENSE, COLLABORATION AND ASSET ACQUISITION AGREEMENTS - Schedule of Costs Accumulated to Acquire Biospecifics (Details) - BioSpecifics - USD ($) $ in Thousands	Dec. 02, 2020	Dec. 01, 2020
Collaborative Arrangement and Arrangement Other than Collaborative
Base purchase price	$ 650,029
Vested employee options and benefits	10,280
Transaction costs	10,268
Less: royalty obligations discharged	(14,909)
Total acquisition consideration	$ 655,668
Number of shares issued as a part of asset acquisition (in shares)		6,159,975
Business acquisition, equity interest canceled, not tendered (in shares)		1,184,980